home · filing · 0000950170-25-065057
8-K filed May 7, 2025, 7:59 PM ET
ticker HURA
CIK 0001498382
M&A
confidence high
sentiment neutral
materiality 0.65
TuHURA amends Kineta merger; revises consideration, extends end date to June 30, 2025
TuHURA Biosciences, Inc./NV
First Amendment revises merger consideration: Initial Stock Consideration based on $16.5M less adjustments at $5.7528/share.
Delayed Stock Consideration set at $6.5M less liabilities and working capital deficits, divided by share value and fully diluted shares.
Cash Consideration base $12M, with credits for $5M exclusivity, $300K extension, $695K advances, loaned amount, and working capital adjustment.
End Date extended to June 30, 2025; closing condition requires TuHURA to receive at least $20M from concurrent investment.
CSO Dennis Yamashita terminated Dec 16, 2024; severance $145,833 over 5 months, COBRA 6 months, options vest on 65,597 shares.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Effective 2024-12-16
Filed May 7, 2025, 7:59 PM ET
the Separation Agreement confirms that Mr. Yamashita’s employment with TuHURA terminated effective December 16, 2024
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Dennis Yamashita was terminated as Chief Scientific Officer at TuHURA Biosciences, Inc./NV.
Action terminated
Role Chief Scientific Officer
Exact text from the filing
the Separation Agreement confirms that Mr. Yamashita’s employment with TuHURA terminated effective December 16, 2024
View on SEC.gov
Source: SEC EDGAR
accession 0000950170-25-065057
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.